研究甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床疗效
|
摘要
目的探讨甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床疗效。方法将2015年3月至2018年3月在我院肿瘤科治疗的60例晚期非小细胞肺癌患者随机分为两组,对照组采用常规化疗方案,在此基础上观察组服用甲磺酸阿帕替尼片,比较两组患者的近期疗效、肿瘤标准物水平变化、毒副反应。结果观察组临床有效率为86.67%,明显高于对照组的70%(P<0.05);观察组治疗后CEA、CYFR21-1、VEGF、MMP-9水平明显低于对照组(P<0.05);观察组胃肠道反应、骨髓抑制、口腔黏膜炎、肝功能损伤、疲劳等毒副反应发生率明显低于对照组(P<0.05)。结论甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床疗效显著,安全性高,对各肿瘤因子的抑制作用明显,具有积极的临床意义。
Objective To investigate clinical effect of apatinib mesylate tablets in treatment of advanced nonsmall cell lung cancer(NSCLC). Methods Divide 60 cases advanced non-small cell lung cancer(NSCLC) patients in oncology department of our hospital from March 2015 to March 2018 into two groups randomly. Control group was treated with routine chemotherapy. On the basis, observation group was treated with apatinib mesylate tablets.Compare short-term effect, changes of tumor standard substance levels and toxicity of two groups. Results Clinical effective rate of observation group was 86.67%, significantly higher than 70% of control group(P<0.05); CEA, CYFR21-1, VEGF and MMP-9 levels in observation group were significantly lower than control group(P<0.05); incidence of gastrointestinal reactions, bone marrow suppression, oral mucositis, liver function damage and fatigue in observation group was significantly lower than control group(P<0.05). Conclusion Apatinib mesylate tablet has significant effect in treatment of advanced non-small cell lung cancer with high safty and obvious inhibitory effect on various tumor factors, which has positive clinical significance.
Objective To investigate clinical effect of apatinib mesylate tablets in treatment of advanced nonsmall cell lung cancer(NSCLC). Methods Divide 60 cases advanced non-small cell lung cancer(NSCLC) patients in oncology department of our hospital from March 2015 to March 2018 into two groups randomly. Control group was treated with routine chemotherapy. On the basis, observation group was treated with apatinib mesylate tablets.Compare short-term effect, changes of tumor standard substance levels and toxicity of two groups. Results Clinical effective rate of observation group was 86.67%, significantly higher than 70% of control group(P<0.05); CEA, CYFR21-1, VEGF and MMP-9 levels in observation group were significantly lower than control group(P<0.05); incidence of gastrointestinal reactions, bone marrow suppression, oral mucositis, liver function damage and fatigue in observation group was significantly lower than control group(P<0.05). Conclusion Apatinib mesylate tablet has significant effect in treatment of advanced non-small cell lung cancer with high safty and obvious inhibitory effect on various tumor factors, which has positive clinical significance.
引文
[1]李旭,张翠翠,谭红叶,等.甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床效果观察[J].中国生化药物杂志,2016,36(2):91-93.
[2]陈二洪,陈志成,陈敏玲,等.甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床效果评价[J].中国当代医药,2017,24(13):91-93.
[3]陈剑波.甲磺酸阿帕替尼治疗晚期非小细胞肺癌疗效分析[J].中外医疗,2017(12):113-115.
[4]杨涛,李一辉.甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床效果评价[J].中国社区医师,2018,34(7):80-81.
[5]曹恒,王静,纪媛媛,等.甲磺酸阿帕替尼治疗晚期非小细胞肺癌临床观察[J].中华肿瘤防治杂志,2017,24(7):468-471.
[6]范少泷,邹玉环,房芳,等.甲磺酸阿帕替尼治疗驱动基因未明的晚期非小细胞肺癌的观察性研究[J].中国医药导刊,2017,19(11):1150-1154.
[2]陈二洪,陈志成,陈敏玲,等.甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床效果评价[J].中国当代医药,2017,24(13):91-93.
[3]陈剑波.甲磺酸阿帕替尼治疗晚期非小细胞肺癌疗效分析[J].中外医疗,2017(12):113-115.
[4]杨涛,李一辉.甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床效果评价[J].中国社区医师,2018,34(7):80-81.
[5]曹恒,王静,纪媛媛,等.甲磺酸阿帕替尼治疗晚期非小细胞肺癌临床观察[J].中华肿瘤防治杂志,2017,24(7):468-471.
[6]范少泷,邹玉环,房芳,等.甲磺酸阿帕替尼治疗驱动基因未明的晚期非小细胞肺癌的观察性研究[J].中国医药导刊,2017,19(11):1150-1154.